An Evaluation of Nivolumab and Ipilimumab for the Treatment of Resectable Stage III Melanoma

The authors contextualize the emergence of ipilimumab and nivolumab in the adjuvant and neo-adjuvant treatment of resectable stage III melanoma with discussion of pivotal studies, and how they influence the current guidelines.